The case for plant-made veterinary immunotherapeutics

Edward Topp; Rebecca Irwin; Tim McAllister; Martin Lessard; Jussi J. Joensuu; Igor Kolotilin; Udo Conrad; Eva Stöger; Tsafrir Leket-Mor; Heribert Warzecha; J. Chris Hall; Michael D. McLean; Eric Cox; Bert Devriendt; Andrew Potter; Ann Depicker; Vikram Virdi; Larry Holbrook; Ketan Doshi; Marike Dussault; Robert Friendship; Oksana Yarosh; Han Sang Yoo; Jacqueline MacDonald; Rima Menassa

doi:10.1016/j.biotechadv.2016.02.007

The case for plant-made veterinary immunotherapeutics

Edward Topp, Rebecca Irwin, Tim McAllister, Martin Lessard, Jussi J. Joensuu, Igor Kolotilin, Udo Conrad, Eva Stöger, Tsafrir Leket-Mor, Heribert Warzecha, J. Chris Hall, Michael D. McLean, Eric Cox, Bert Devriendt, Andrew Potter, Ann Depicker, Vikram Virdi, Larry Holbrook, Ketan Doshi, Marike DussaultRobert Friendship, Oksana Yarosh, Han Sang Yoo, Jacqueline MacDonald, Rima Menassa

Research output: Contribution to journal › Review article › peer-review

37 Scopus citations

Abstract

The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.

Original language	English (US)
Pages (from-to)	597-604
Number of pages	8
Journal	Biotechnology Advances
Volume	34
Issue number	5
DOIs	https://doi.org/10.1016/j.biotechadv.2016.02.007
State	Published - Sep 1 2016

Keywords

Antibiotic resistance
Antibody
Immunotherapeutic
Livestock production
Molecular farming
Plant biotechnology
Recombinant protein
Veterinary vaccine

ASJC Scopus subject areas

Biotechnology
Bioengineering
Applied Microbiology and Biotechnology

Access to Document

10.1016/j.biotechadv.2016.02.007

Cite this

Topp, E., Irwin, R., McAllister, T., Lessard, M., Joensuu, J. J., Kolotilin, I., Conrad, U., Stöger, E., Leket-Mor, T., Warzecha, H., Hall, J. C., McLean, M. D., Cox, E., Devriendt, B., Potter, A., Depicker, A., Virdi, V., Holbrook, L., Doshi, K., ... Menassa, R. (2016). The case for plant-made veterinary immunotherapeutics. Biotechnology Advances, 34(5), 597-604. https://doi.org/10.1016/j.biotechadv.2016.02.007

Topp, E, Irwin, R, McAllister, T, Lessard, M, Joensuu, JJ, Kolotilin, I, Conrad, U, Stöger, E, Leket-Mor, T, Warzecha, H, Hall, JC, McLean, MD, Cox, E, Devriendt, B, Potter, A, Depicker, A, Virdi, V, Holbrook, L, Doshi, K, Dussault, M, Friendship, R, Yarosh, O, Yoo, HS, MacDonald, J & Menassa, R 2016, 'The case for plant-made veterinary immunotherapeutics', Biotechnology Advances, vol. 34, no. 5, pp. 597-604. https://doi.org/10.1016/j.biotechadv.2016.02.007

@article{c1adc82ba80e484594a3dc3571d0aa1b,

title = "The case for plant-made veterinary immunotherapeutics",

abstract = "The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.",

keywords = "Antibiotic resistance, Antibody, Immunotherapeutic, Livestock production, Molecular farming, Plant biotechnology, Recombinant protein, Veterinary vaccine",

author = "Edward Topp and Rebecca Irwin and Tim McAllister and Martin Lessard and Joensuu, {Jussi J.} and Igor Kolotilin and Udo Conrad and Eva St{\"o}ger and Tsafrir Leket-Mor and Heribert Warzecha and Hall, {J. Chris} and McLean, {Michael D.} and Eric Cox and Bert Devriendt and Andrew Potter and Ann Depicker and Vikram Virdi and Larry Holbrook and Ketan Doshi and Marike Dussault and Robert Friendship and Oksana Yarosh and Yoo, {Han Sang} and Jacqueline MacDonald and Rima Menassa",

note = "Funding Information: This collaborative manuscript is an output from a workshop held in London, Ontario on September 23–25, 2013 and sponsored by the OECD Co-operative Research Programme on Biological Resource Management for Sustainable Agricultural Systems, whose financial support made it possible for some of the invited speakers to attend. Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = sep,

day = "1",

doi = "10.1016/j.biotechadv.2016.02.007",

language = "English (US)",

volume = "34",

pages = "597--604",

journal = "Biotechnology Advances",

issn = "0734-9750",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - The case for plant-made veterinary immunotherapeutics

AU - Topp, Edward

AU - Irwin, Rebecca

AU - McAllister, Tim

AU - Lessard, Martin

AU - Joensuu, Jussi J.

AU - Kolotilin, Igor

AU - Conrad, Udo

AU - Stöger, Eva

AU - Leket-Mor, Tsafrir

AU - Warzecha, Heribert

AU - Hall, J. Chris

AU - McLean, Michael D.

AU - Cox, Eric

AU - Devriendt, Bert

AU - Potter, Andrew

AU - Depicker, Ann

AU - Virdi, Vikram

AU - Holbrook, Larry

AU - Doshi, Ketan

AU - Dussault, Marike

AU - Friendship, Robert

AU - Yarosh, Oksana

AU - Yoo, Han Sang

AU - MacDonald, Jacqueline

AU - Menassa, Rima

N1 - Funding Information: This collaborative manuscript is an output from a workshop held in London, Ontario on September 23–25, 2013 and sponsored by the OECD Co-operative Research Programme on Biological Resource Management for Sustainable Agricultural Systems, whose financial support made it possible for some of the invited speakers to attend. Publisher Copyright: © 2016

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.

AB - The excessive use of antibiotics in food animal production has contributed to resistance in pathogenic bacteria, thereby triggering regulations and consumer demands to limit their use. Alternatives for disease control are therefore required that are cost-effective and compatible with intensive production. While vaccines are widely used and effective, they are available against a minority of animal diseases, and development of novel vaccines and other immunotherapeutics is therefore needed. Production of such proteins recombinantly in plants can provide products that are effective and safe, can be orally administered with minimal processing, and are easily scalable with a relatively low capital investment. The present report thus advocates the use of plants for producing vaccines and antibodies to protect farm animals from diseases that have thus far been managed with antibiotics; and highlights recent advances in product efficacy, competitiveness, and regulatory approval.

KW - Antibiotic resistance

KW - Antibody

KW - Immunotherapeutic

KW - Livestock production

KW - Molecular farming

KW - Plant biotechnology

KW - Recombinant protein

KW - Veterinary vaccine

UR - http://www.scopus.com/inward/record.url?scp=84958230932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958230932&partnerID=8YFLogxK

U2 - 10.1016/j.biotechadv.2016.02.007

DO - 10.1016/j.biotechadv.2016.02.007

M3 - Review article

C2 - 26875776

AN - SCOPUS:84958230932

SN - 0734-9750

VL - 34

SP - 597

EP - 604

JO - Biotechnology Advances

JF - Biotechnology Advances

IS - 5

ER -

The case for plant-made veterinary immunotherapeutics

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this